The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
PegramM.D.PienkowskiT.NorthfeltD.W.Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst.2004; 96(10): 759–769.
ValeroV.ForbesJ.PegramM.D.Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol.2011; 29(2): 149–156.
CoudertB.P.LargillierR.ArnouldL.Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol.2007; 25(19): 2678–2684.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Breast cancer. V.2.2012. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed October 3, 2011.
9.
CohenM.R.SmetzerJ.Preparing for a damaging medication error. ISMP Med Safety Alert!1999; 4: 14.
10.
SavareseD.TaplinM.E.HalabiS.HarsV.KreisW.VogelzegangN.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5 suppl. 17): 39–44.
11.
CheungY.W.CradockJ.C.VishnuvajjalaB.R.FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines: Antiemesis. V.1.2012. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed December 16, 2011.
14.
BaschE.PrestrudA.A.HeskethP.J.Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2011; 29(31): 4189–4198.
15.
Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology. Antiemetic guidelines 2011. Multinational Association for Supportive Care in Cancer Web site. Published April 2011. Accessed December 16, 2011.
16.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
17.
HeskethP.J.KrisM.G.GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
18.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
19.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
20.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19; 85(8): 1099–1101.
21.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
22.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
SmithT.J.KhatcheressianJ.LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
25.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors. V.1.2011. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed December 10, 2011.
26.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
27.
AronoffG.R.BennettW.M.BernsJ.S.Drug Pre-scribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
